Oramed Pharmaceuticals Inc.
Company Snapshot: Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed’s Protein Oral Delivery (POD™) technology is based on over 30 years of research by top scientists at Jerusalem’s Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).
- Mar 19 2020 Oramed Receives Positive Feedback From End-of-Phase 2 Oral Insulin CMC Meeting With FDA
- Feb 27 2020 Oramed Pharmaceuticals Inc. Prices Public Offering of Common Stock for Aggregate Proceeds of $21 Million
- Feb 26 2020 Oramed Pharmaceuticals Inc. Announces Proposed Public Offering of Common Stock
- Feb 26 2020 Oramed Reports Positive Results in the Final Cohort of Its Phase 2b Oral Insulin Trial
- Feb 4 2020 Oramed to Present at BIO CEO & Investor Conference